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Summary
Tuberculosis (TB) remains a global health pandemic.  The current depiction of the Mycobacterium 
tuberculosis (Mtb) life cycle proposes that airborne bacilli are inhaled, phagocytosed by alveolar 
macrophages, resulting in formation of a granuloma which ruptures into the airways to re-initiate the 
infectious cycle.  However, this widely proposed model overlooks the fact established 100 years ago 
that the initial site of Mtb implantation is in the lower zones of the lungs, while infectious cavitary 
pulmonary disease develops at the lung apices.  The immunological events at these two pulmonary 
locations are different; cavitation does not occur in the bases, only the apices.  However, the current 
conceptual model of TB considers the immunology of these two temporally and spatially separated 
events to be identical.  One key consequence is that prevention of primary childhood TB at the lung 
bases is regarded adequate immunological protection, but extensive evidence demonstrates that 
greater immunity may predispose to immunopathology and transmission at the lung apex.  Addressing 
time and place in human TB immunology suggests that much greater understanding of 
immunopathological mechanisms of TB is required before performing further pre-exposure 
vaccination trials.  
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The life cycle of Mycobacterium tuberculosis in man
Mycobacterium tuberculosis (Mtb) causes the disease tuberculosis (TB) and is an obligate human 
pathogen.  TB may affect any organ 1, but the life cycle is only completed when it causes pulmonary 
immunopathology, which drives aerosolisation of bacilli and transmission to a new host 2.  Alberto 
Ghon identified in 1914 that the initial site of infection after exposure is in the well ventilated lower 
zones of the lungs 3 and this finding has been confirmed in many subsequent post mortem studies 4, 5.
Even before then, Morgagni and Laennec had identified that active pulmonary TB occurs 
predominantly in the apical segments of the upper lobes 6, although it may also cause cavities in the 
apices of the lower lobes.  Therefore, the TB life cycle involves an initial seeding event in the well 
ventilated lung bases, followed by dissemination to a second location at the lung apices, where 
immunopathology may lead to lung destruction and transmission.
However, the widespread depiction in the scientific literature of the Mtb life cycle suggests that these 
events all occur at a single location 7-10 (Figure 1).  While some simplification can be justified to 
summarise complex biological phenomena, we feel that this generalization is now hampering research 
and understanding of the disease.  In the TB field, it appears that the recognized syndrome of theory-
induced blindness, where data contradicting a long-held theory are dismissed 11, has taken hold.  The 
current model omits key complexities in the host immune response to Mtb that may lead to the pursuit 
of ultimately flawed therapeutic and vaccination strategies.
The immunological events at the lung base and apex are different
The clinical features of human TB demonstrate that there are key differences in the host immune 
response to Mtb at the two pulmonary loci.  When initially inhaled to the lower zones of the lung, Mtb 
will cause primary consolidative pneumonia or lymphadenitis in a small proportion of individuals 
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(less than 5%), most commonly in very young children 12, but cavitating pneumonia almost never 
develops (Figure 2A).  Disseminated TB may occur either as miliary TB with small granulomas 
throughout both lung fields, or TB meningitis, but neither are associated with pulmonary cavitation.  
In contrast, from the age of puberty, secondary or reactivation of TB can develop, peaking in early 
adulthood 13.  This is a very different phenomenon.  First, the location is either the lung apices or the 
apex of the lower lobes 14.  Secondly, progressive tissue destruction occurs, resulting in pulmonary 
cavity formation (Figure 2B).  Histologically, the pulmonary lesions of primary TB differ from post-
primary TB, with greater bacterial load, reduced lipid accumulation and an acute inflammatory 
response in primary disease compared to secondary disease 15.  The clinical spectrum of disease 
demonstrates that the immunological events at the two pulmonary loci must be significantly different. 
In the majority of individuals, the initial primary infection is self-limiting.  It is estimated that 90% of 
those exposed to Mtb will control infection life-long 16, while in approximately 5% of exposed 
individuals, pulmonary pathology will develop at a later time point at the lung apices resulting in 
cavitation and transmission.  The precise mechanistic events are poorly understood but some 
inferences can be made from clinical observations.  CD4+ T cells play a complex role in the host-
pathogen interaction; CD4 T cells are necessary for protection from clinical disease, as manifested by 
the high incidence of TB in the context of HIV infection, but at the same time are necessary for 
immune-mediated tissue destruction, since patients with advanced HIV infection very rarely develop 
pulmonary cavitation 17.  Furthermore, as the immune system reconstitutes with anti-retroviral 
therapy, immunopathology with lung infiltrates and cavitation often develops 17.  Whilst the current 
paradigm suggests that granulomas rupture into the airway 8, post-mortem studies suggest that cavities 
in fact develop in areas of necrotizing lipoid pneumonia, where infected foamy alveolar macrophages 
predominate, in association with infarction due to vasculitis and bronchial obstruction 15, 18.  The 
process of cavitation in the lung apices is driven by a very low bacterial load and in association with 
strong host immunity 15, which contrasts necrotic mouse models where the bacterial load is extremely 
high 19.
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Cavitation typically occurs at the apex of the upper lobes, though can also occur at the apices of the 
lower lobes.  Historically, this regional distribution was thought to be due to differential oxygen 
distribution 6.  However, alternative hypotheses have been suggested, such as differential lymphatic 
drainage 20 or reduced blood flow 15.  Enzymes such as the collagenase matrix metalloproteinase-1
must be the final effectors of extracellular matrix destruction that leads to cavity formation 21, 22, and 
collagen breakdown favours Mtb in the host-pathogen interaction 23.  Therefore, alternative 
hypotheses for the apical localization would include increased susceptibility to extracellular matrix 
breakdown, due to reduced availability of plasma antiproteases and the increased susceptibility of 
collagen under tension to enzymatic cleavage  24, or the modulation of cellular biology by tissue 
stiffness 25 . Excessive neutrophil influx may exacerbate pathology 26.  Investigation of these 
competing hypotheses is hindered by the need to study relatively large animal models to investigate 
cavity formation, such as the rabbit 27. Therefore, the precise dissection of the underlying 
mechanisms, and the specific role of T cells in cavitation, has been hindered by the lack of suitable 
models 28.  Consequently, we do not understand the key mechanisms which lead to disease 
transmission, nor why over 90% of exposed individuals do not develop such pathology 29.
Implications of distinguishing primary and secondary disease
A current central focus of TB research is vaccination, including both pre-exposure and post-exposure 
strategies30-32.  BCG vaccination protects from childhood but not adult TB 33, demonstrating that 
protection from primary disease does not equate to protection from secondary reactivation of TB.  The 
recent phase 2b trial of the novel vaccine candidate, MVA85A, did not show any efficacy preventing 
TB infection in infants, but the 37 month follow-up period is insufficient to determine whether the 
modulation of the cell-mediated immune response will increase the incidence of cavitary pulmonary 
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TB after puberty.  Since 90% of individuals will control infection lifelong, any perturbation of the 
immunological equipoise that leads to containment of infection and leads to cavitary pathology may 
inadvertently increase disease incidence.   Such an increase in infectious patients has the potential to 
greatly increase transmission in the longer term 2.   However, this potential harm is currently rarely 
considered and follow-up periods in clinical trials are too brief to exclude this adverse outcome.  
Furthering this concern, experimental data demonstrate that vaccination can worsen immune-mediated
tissue damage in the mouse 34, which lacks the key collagenases driving tissue destruction 35.  In the 
rabbit model, pre-sensitisation with PPD to drive a strong cellular immune response increases the 
frequency of pulmonary cavitation 36 and perhaps unexpectedly according to current paradigms, 
immunosupression with azathioprine prevents cavity formation 37.  In humans, Virchow recognised 
that tuberculin treatment could cause breakdown of pulmonary granulomas 38 and epidemiological 
studies demonstrate that a stronger Mantoux test in childhood is associated with the subsequent 
development of pulmonary disease in adulthood 39.  In advanced HIV infection where the 
inflammatory innate response is decreased 40, cavitation does not occur but may develop during 
immune reconstitution after antiretroviral treatment 17.  Taken together, these observations 
demonstrate that an enhanced immune response can drive lung destruction and pathology at the lung 
apices, but this will only become apparent in early adulthood.
Is prevention of transmission the solution?
Developing a novel pre-exposure vaccine is hindered by the limitations of current animal models, 
none of which fully reflect the complexity of human disease in man, and the decades of follow-up
needed for human pre-exposure vaccination trials.  Since we cannot be certain that pre-exposure 
vaccination will not inadvertently worsen the TB pandemic without prohibitively long studies, 
alternative approaches should be explored 41. For example, post-exposure vaccination that prevents 
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infectious pulmonary TB would break the cycle of transmission.  Vaccination of 16 to 20-year-olds 
with immunological evidence of Mtb exposure would require approximately three years follow-up to 
determine if such an approach would improve the host immune response at the lung apex, thereby 
reducing infectious pulmonary disease. This has the potential to reduce the transmission of Mtb and 
thereby the incidence of childhood TB.
An alternative approach to vaccination would be to combine improved case finding with novel 
treatment regimes.  The TB control strategy of active case finding is well established 42, and in 
combination with chemoprophylaxis of latent TB is a mainstay of controlling TB in low incidence 
countries 43.  For the developing world, active case finding could be strengthened by incorporation of 
novel biomarkers of active pulmonary TB 44.  The development of near-patient assays would 
revolutionize population screening.  Assays could combine both pathogen and host-derived factors 
such as liporabinomannan and matrix degradation products to identify the aerosol super-shedders who 
drive the pandemic 45, 46.  A panel of biomarkers may permit assays that can be implemented for 
screening the entire adult population.  The diagnostic test does not require high specificity, only high 
sensitivity, as the next investigation for an individual with a “possible pulmonary TB” result would be 
a chest x-ray and sputum smear, which is very specific for pulmonary TB 47.  Novel treatment 
approaches may incorporate host-directed therapies to reduce pathology and accelerate bacterial 
clearance 48.  By identifying and treating infectious individuals, this approach would break the 
infectious cycle and prevent childhood TB, thereby achieving exactly the same goal as pre-exposure 
vaccination without the concern of delayed adverse events.
Conclusion
Reconsidering long-established features of human TB identifies a fundamental inconsistency between 
clinical disease and widely-proposed paradigms of TB immunology in the research arena.  Primary 
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TB is a distinct clinical and immunological entity from secondary disease, the form that transmits 
infection. There is a need to reconsider the conceptual framework of the optimal host TB immune 
response to incorporate both time and place.  One immediate consequence is that complex issues 
regarding pre-exposure vaccination approaches are apparent and a better understanding of 
immunological events in primary and secondary TB is urgently required.    Approaches such as post-
exposure vaccination of young adults and innovative methods of TB case finding and treatment 
should be a central strategy of future TB research.
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Figure legends
Figure 1:  The TB life cycle involves two distinct immunological loci.  The widely 
depicted life cycle of Mycobacterium tuberculosis implies all events happen at a single locus.
Aerosolised Mtb is inhaled, phagocytosed by alveolar macrophages, a granuloma forms 
which ultimately breaks down and ruptures into an airway, completing the cycle.  However, 
this neglects the fact that the initial implantation of aerosolised Mtb is the lung bases (A, 
arrow indicates calcified Ghon focus), while infectious cavitary pulmonary TB occurs at the 
lung apices (B, arrow indicates cavity).  Cavitation does not occur at the site of initial 
implantation, demonstrating that the immunology of these loci is different, but the current 
paradigm implies a single immunological process.
Figure 2:  Immunological events differ between the lung base and apex. Childhood 
pulmonary TB causes a primary pneumonia in the lower zones of the lungs, which does not 
cavitate (A).  In contrast, adult pulmonary TB occurs at the lung apices, and causes extensive 
cavitation (B).
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Figure 1:  The TB life cycle involves two disnct immunological loci.  The widely depicted life cycle 
of Mycobacterium tuberculosis implies all events happen at a single locus.  Aerosolised Mtb is 
inhaled, phagocytosed by alveolar macrophages, a granuloma forms which ulmately breaks down 
and ruptures into an airway, compleng the cycle.  However, this neglects the fact that the inial 
implantaon of aerosolised Mtb is the lung bases (A, arrow indicates calcied Ghon focus), while 
infecous cavitary pulmonary TB occurs at the lung apices (B, arrow indicates cavity).  Cavitaon 
does not occur at the site of inial implantaon, demonstrang that the immunology of these loci is 
dierent, but the current paradigm implies a single immunological process.   
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Figure 2:  Immunological events dier between the lung base and apex.  Childhood pulmonary TB 
causes a primary pneumonia in the lower zones of the lungs, which does not cavitate (A).  In 
contrast, adult pulmonary TB occurs at the lung apices, and causes extensive cavitaon (B). 
